Related Experiment Video
Updated: Jun 5, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols
Hanna Ksiezak-Reding1, Lap Ho, Ismael Santa-Maria
1Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. hanna.reding@mssm.edu
Abstract:
Abnormal folding of the microtubule-associated protein tau leads to aggregation of tau into paired helical filaments (PHFs) and neurofibrillary tangles, the major hallmark of Alzheimer's disease (AD). We have recently shown that grape seed polyphenol extract (GSPE) reduces tau pathology in the TMHT mouse model of tauopathy (Wang et al., 2010). In the present studies we assessed the impact of GSPE exposure on the ultrastructure of PHFs isolated from Alzheimer's disease brain. Transmission electron microscopy revealed that GSPE induced profound dose- and time-dependent alterations in the morphology of PHFs with partial disintegration of filaments. Filaments showed ∼2-fold enlargement in width and displayed numerous protrusions and splayed ends consistent with unfolding of tau and diminished structural stability. In addition, GSPE induced a reduction in immunogold labeling with antibodies against the C-terminal half (12E8, PHF-1) and the middle region of tau (AT8, Tau5, pSer214 tau, and AT180) but not the C-terminal end (Tau46). In comparison, labeling of N-terminus (Alz50) was enhanced. It is unlikely that alterations in immunogold labeling were due to biochemical alterations, e.g., protein phosphatase or proteolytic activities potentially stimulated by GSPE, because western blotting studies have shown the preservation of full length polypeptides of tau and their phospho-epitopes in GSPE-treated samples. The GSPE mechanism may include a noncovalent interaction of polyphenols with proline residues in the proline-rich domain of tau, with Pin1 sites at P213 and P232 most seriously affected as judged by suppression of labeling. Collectively, our results suggest that GSPE has a significant potential for therapeutic development by neutralizing phospho-epitopes and disrupting fibrillary conformation leading to disintegration of PHFs.
Insights
Grape seed polyphenol extract (GSPE) disrupts the structure of pathological tau filaments in Alzheimer's disease (AD) brains. GSPE treatment alters tau ultrastructure, potentially offering a therapeutic strategy for AD by neutralizing toxic tau aggregates.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Abnormal tau protein folding causes paired helical filaments (PHFs) and neurofibrillary tangles, key markers of Alzheimer's disease (AD).
- Grape seed polyphenol extract (GSPE) has previously demonstrated efficacy in reducing tau pathology in mouse models.
Purpose of the Study:
- To investigate the effects of GSPE on the ultrastructure of PHFs isolated from human Alzheimer's disease brains.
- To elucidate the potential therapeutic mechanisms of GSPE in neutralizing tau pathology.
Main Methods:
- Transmission electron microscopy (TEM) was used to analyze PHF morphology after GSPE exposure.
- Immunogold labeling with various anti-tau antibodies assessed changes in protein epitopes.
- Western blotting confirmed the preservation of tau polypeptides and phospho-epitopes.
Main Results:
- GSPE induced dose- and time-dependent alterations in PHF morphology, including partial disintegration.
- Filaments widened and showed signs of unfolding, indicating reduced structural stability.
- GSPE reduced labeling for mid- and C-terminal tau epitopes while enhancing N-terminal labeling, suggesting specific interactions.
Conclusions:
- GSPE significantly alters the ultrastructure and conformation of PHFs, leading to their disintegration.
- The mechanism likely involves noncovalent interactions between polyphenols and proline-rich regions of tau.
- GSPE shows therapeutic potential for Alzheimer's disease by disrupting toxic tau aggregates.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Alzheimer's Disease: Treatment
